Are Peptides Legal in Australia?

Many peptides are controlled in Australia as prescription-only substances, and unapproved peptide products generally cannot be lawfully supplied outside tightly defined pathways. The national scheduling system placed BPC-157 in Schedule 4, the prescription-only schedule, from 1 June 2024, and in April 2026 the Therapeutic Goods Administration (TGA) issued a safety alert about the rising import, supply, compounding and advertising of unapproved peptide products 13.

This page explains the TGA's position and why Australia is generally regarded as the strictest of the common-law markets. It is a companion to the site's page on Ireland, and it does not repeat the general reasons countries diverge, which have their own article. It is an explanation of a regulatory system, not legal advice and not a guide to obtaining anything.

Who regulates peptides in Australia?

The TGA regulates therapeutic goods nationally, and the states and territories apply the scheduling of substances through their own poisons laws. Two national instruments matter most: the register of approved therapeutic goods, which lists what may be supplied, and the Poisons Standard, which sorts substances into schedules that decide who may supply and possess them 13.

That split is the first reason the Australian system is layered. A product can fail to be approved at the national level while its active substance is also controlled at the state level, and each layer carries its own offences.

What does Schedule 4 mean?

Schedule 4 is the prescription-only schedule: substances in it may be supplied only on the prescription of an authorised practitioner. Many approved peptide medicines sit there, including the GLP-1 receptor agonists and insulin products, which Australians obtain through a doctor and a pharmacy 2.

BPC-157 is the clearest example of a research peptide being scheduled by name. After advisory committee meetings in November 2023, the final decision created a Schedule 4 entry for BPC-157 with effect from 1 June 2024. The stated purpose was to prohibit possession without appropriate authorisation and to align BPC-157 with other performance- and image-enhancing substances, and the proposal was prompted by 48 referrals for importation of BPC-157 that the TGA had received since 1 July 2022 3. Because no approved product contained it, the committee saw no reason to delay the change 3.

The point to take from that is structural. In Australia a substance can be controlled by name even though no medicine containing it has ever been approved, so the absence of an approved product does not leave a compound unregulated.

What does "unapproved" mean in Australia?

It means a product that has not been assessed and entered on the national register of therapeutic goods, so no Australian authority has examined its safety, its quality or whether it does what is claimed. That is the sense in which the TGA uses the word throughout its peptide alert 1.

Unapproved is not the same as scheduled, and the two are easy to confuse. Approval is about a product: this preparation, from this sponsor, for this use. Scheduling is about a substance: who may supply or possess it, whatever product it appears in. BPC-157 is unapproved, because no product containing it has been assessed, and it is also scheduled, because the substance itself is in Schedule 4 3. Retatrutide appears in the same alert as an unapproved product 1. A compound can be one without the other, and the controls stack rather than substitute.

What did the TGA warn about in April 2026?

A rise in the import, supply, compounding and advertising of unapproved peptide products, and the harm they were causing. The TGA's safety alert of 13 April 2026 named products containing BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295, often supplied in injectable form, and stressed that none had been assessed by the TGA for safety, quality or effectiveness 1.

The alert reported adverse events including severe allergic reactions that required adrenaline and hospitalisation 1. Reporting of the alert listed further events, among them severe inflammation, full-body itching, palpitations, blurred vision and musculoskeletal injuries, and noted that the most serious breaches of the law carry penalties of up to $16.5 million in fines or seven years' imprisonment 2.

The alert was addressed to practitioners and pharmacies as much as to consumers, and its title says so: it concerns responsibilities when importing, compounding and supplying unapproved peptide products 1. That reflects the TGA's view that part of the problem was coming through clinics and compounding rather than only through overseas websites.

What is the personal importation scheme, and does it cover peptides?

It is a narrow exemption that lets an individual bring in an unapproved therapeutic good for their own treatment, and for prescription-only substances it requires a valid Australian prescription. The scheme's conditions limit each order to three months' supply and the total to fifteen months' supply in a year, and the goods may not be sold, supplied or given to anyone else 4.

It is widely misunderstood, which is why it belongs in an article like this. The scheme exists so that a patient under a doctor's care can obtain a medicine not available in Australia. It is not a general allowance for unapproved substances, it does not cover a Schedule 4 substance without an Australian prescription, and it has nothing to do with laboratory research or with supplying others 4. Treating it as a loophole misreads its purpose and its conditions.

Why is Australia stricter than other common-law countries?

Because it controls these substances at more points and by name. Compared with the United Kingdom, Ireland or the United States, where the main question for an unapproved peptide is usually whether it is being presented as a medicine, Australia adds scheduling of specific substances, possession controls for performance- and image-enhancing substances, and a prescription requirement that applies at the border 34.

1. Scheduling by name. A substance such as BPC-157 is prescription-only regardless of how it is labelled or presented.
2. Possession, not only supply. The BPC-157 decision was expressly about restricting possession without authorisation.
3. The border. Importing a prescription-only substance for personal treatment needs an Australian prescription, and supply to others is outside the patient scheme altogether.
4. Advertising. Prescription medicines may not be advertised to the public, and the restriction reaches online promotion.
5. Active enforcement. The April 2026 alert shows the TGA treating unapproved peptides as a current compliance priority.

The advertising point deserves a sentence of its own. The TGA's guidance is explicit that prescription medicines are generally prohibited from being advertised to the public, and that adding a disclaimer or a caveat, such as advising people to speak with a health practitioner, does not exempt material from the restriction 5.

Does a research label change the position in Australia?

No. Scheduling attaches to the substance, so a Schedule 4 entry applies whatever words are printed on the container 3. That is the sharpest difference from systems built mainly on a presentation test, where a label is at least one piece of evidence. In Australia, for a scheduled substance, the label is not the question.

State and territory poisons laws have their own authorisation arrangements for people and institutions who legitimately handle scheduled substances. Those arrangements belong to the relevant state authority, vary between jurisdictions, and are not something this page can summarise responsibly.

Does the FDA's April 2026 change affect Australia?

No. The FDA removed twelve peptides, including BPC-157 and TB-500, from a category in the American compounding rules. That decision concerns what United States pharmacies may do. It has no effect on the Poisons Standard, on the TGA's register, or on state poisons law, and BPC-157 remains in Schedule 4 in Australia 3.

So are peptides legal in Australia?

Approved peptide medicines are lawful on prescription; unapproved peptide products are, in the TGA's words, unassessed for safety, quality or effectiveness, and supplying them outside the approved pathways can be unlawful 1. For a substance scheduled by name, such as BPC-157, possession without authorisation is itself controlled 3.

That makes Australia the clearest case in this cluster of a system where the answer depends less on presentation and more on the substance. A specific question still needs a specific answer, from the TGA, the relevant state or territory authority, or a qualified professional in Australia.